Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Cancer research shows 'tiny radioacative beads' could dramatically hinder tumor growth

Bowel cancer patients were treated using 'resin microspheres' alongside chemotherapy

Alexander Sehmer
Monday 01 June 2015 06:28 BST
Comments
A woman receives chemotherapy treatment for cancer
A woman receives chemotherapy treatment for cancer (Getty)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

A cancer treatment that uses tiny radioactive beads fired at tumours can dramatically hinder a tumour's growth, according to new research.

The treatment used "resin microspheres" alongside chemotherapy on patients with bowel cancer that had spread to the liver.

Research results showed it halted the growth of liver tumours for almost eight months longer than chemotherapy alone.

In 6% or cases it sent the cancer into remission, three times more frequently than when treated using only chemotherapy.

It examined the effectiveness of what is known as selective internal radiation therapy (SIRT) or "radioembolisation", with 530 people receiving the treatment.

The research findings were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago by Associate Professor Peter Gibbs of The Royal Melbourne Hospital in Australia.

Professor Gibbs said the findings were important because bowel cancer, also known as colorectal cancer, typically spreads to the liver before affecting other organs.

The microspheres used are about a third of the width of a human hair and contain the radioactive isotope yttrium-90 which is used in cancer treatment.

The balls are delivered via a catheter directly into cancer-affected parts of the liver through the tumours' own networks of blood vessels.

They then become permanently lodged in the small blood vessels surrounding a tumour and starve it, while having a minimal impact on surrounding healthy tissue although they continue to generate radiation for weeks after treatment.

The therapy is already approved in the EU for treating certain types of liver cancer.

The Sirtex trial is one of three trials underway for the microspheres treatment. Another is being undertaken by Oxford University.

(Additional reporting by PA)

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in